

17 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/17/3189050/0/en/FDA-Accepts-Supplemental-New-Drug-Application-for-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-the-Treatment-of-Plaque-Psoriasis-in-Children-Ages-2-to-5.html

30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177307/0/en/Arcutis-Launches-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis-in-Children-Ages-2-to-5.html

30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177526/0/en/Mother-Daughter-Duo-Tori-Spelling-and-Stella-McDermott-Partner-With-Arcutis-Biotherapeutics-in-the-Free-to-Be-Me-Campaign-Urging-People-With-Inflammatory-Skin-Conditions-to-Speak-W.html

28 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/28/3175418/0/en/Arcutis-Outlines-Strategy-for-Driving-Sustainable-Growth-and-Announces-Third-Quarter-2025-Financial-Results.html

24 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/24/3172762/0/en/Arcutis-to-Present-New-Quality-of-Life-and-Long-Term-Data-with-ZORYVE-roflumilast-Cream-0-15-and-0-05-for-the-Treatment-of-Atopic-Dermatitis-at-the-Fall-Clinical-Dermatology-Confer.html

06 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/06/3161656/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Atopic-Dermatitis-in-Children-Ages-2-to-5.html